Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Entera Bio Ltd.

Get SEC filing alerts via email and in your feed for Entera Bio Ltd.

ENTX ENTXW

Entera Bio Ltd.

About Entera Bio Ltd.

Entera Bio Ltd. develops oral peptide and protein replacement therapies targeting chronic conditions like osteoporosis and hypoparathyroidism. Utilizing its proprietary N-Tab platform, the company aims to replace injectable treatments with convenient daily tablets. Its pipeline includes first-in-class oral PTH and GLP programs, focusing on underserved markets and leveraging strategic collaborations to advance innovative, patient-friendly therapeutics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Entera Bio Ltd.

1
1
Entera Bio Ltd. Entera Bio Reports $3.5 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Entera Bio Ltd. Entera Bio Reports $11.4 Million Net Loss and 77% Revenue Decline for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Entera Bio Ltd. Entera Bio Reports Financial Results for Q3 and Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Entera Bio Ltd. Entera Bio Reports $5.2 Million Net Loss in Q2 2025, Revenue Declines to $42,000

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Entera Bio Ltd. Entera Bio Reports Q1 2025 Financial Results with Increased Net Loss and Revenue Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Entera Bio Ltd. Entera Bio Reports $9.5 Million Net Loss for Fiscal Year 2024, Revenue Increases to $181,000

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Entera Bio Ltd. Entera Bio Reports Significant Revenue Growth, Net Loss in Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments